
Telomir Pharmaceuticals, Inc. — Investor Relations & Filings
Telomir Pharmaceuticals, Inc. is a pre-clinical stage pharmaceutical company focused on the development of Telomir-1, its lead product candidate. Telomir-1 is an investigational oral small molecule designed to address the cellular drivers of aging and chronic disease. Its proposed mechanism of action involves regulating intracellular metals, such as iron and copper, to interrupt enzyme function. The therapy aims to extend and protect telomeres, reset abnormal DNA methylation patterns, reduce oxidative stress, and restore mitochondrial function. By targeting these fundamental processes, the company seeks to develop treatments for age-related conditions and specific disorders like Wilson's Disease.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-20 | English | |
| 10-Q | 2026-05-14 | English | |
| 8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer) | 2026-04-24 | English | |
| 8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer) | 2026-03-31 | English | |
| 8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer) | 2026-03-31 | English | |
| 8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer) | 2026-03-27 | English |
Browse filings by year
4 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
13 filings
| |||||
| 46642344 | 8-K | 2026-05-20 | English | ||
| 46209544 | 10-Q | 2026-05-14 | English | ||
| 36131700 | 8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer) | 2026-04-24 | English | ||
| 33116048 | 8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer) | 2026-03-31 | English | ||
| 33112612 | 8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer) | 2026-03-31 | English | ||
| 33066053 | 8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer) | 2026-03-27 | English | ||
| 32968038 | 10-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer) | 2026-03-17 | English | ||
| 32267969 | 8-K Filing | 2026-02-17 | English | ||
| 32267919 | SCHEDULE 13G/A Filing | 2026-02-12 | English | ||
| 32267961 | 8-K Filing | 2026-02-05 | English | ||
| 13650689 | PRER14A | 2026-01-23 | English | ||
| 13650688 | 8-K | 2026-01-10 | English | ||
| 13650690 | 8-K | 2026-01-05 | English | ||
|
2025
2 filings
| |||||
| 13650691 | 8-K | 2025-12-20 | English | ||
| 13650692 | 8-K | 2025-12-17 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Asarina Pharma AB
A biotechnology company in liquidation, formerly focused on…
|
ASAP | SE | Professional, scientific and te… |
|
Atara Biotherapeutics, Inc.
Develops off-the-shelf allogeneic T-cell immunotherapies fo…
|
ATRA | US | Professional, scientific and te… |
|
ATUM CO., LTD.
An integrated biologics development partner offering servic…
|
355690 | KR | Professional, scientific and te… |
|
AUREKA LIMITED
Accelerates drug discovery and development using AI and com…
|
AKA | AU | Professional, scientific and te… |
|
Avalo Therapeutics, Inc.
Clinical-stage biotech developing treatments for immune-med…
|
AVTX | US | Professional, scientific and te… |
|
Avalyn Pharma Inc.
Developing innovative inhaled therapies for rare respirator…
|
AVLN | US | Professional, scientific and te… |
|
Azenta, Inc.
Offers sample management, storage, and multiomics solutions…
|
AZTA | US | Professional, scientific and te… |
|
Baijin Life Science Holdings Limited
An investment holding company operating in biopharmaceutica…
|
1466 | HK | Professional, scientific and te… |
|
BCAL DIAGNOSTICS LIMITED
Developing a non-invasive blood test for early breast cance…
|
BDX | AU | Professional, scientific and te… |
|
BEBETTER MED INC.
Develops small molecule therapeutics for oncology, metaboli…
|
688759 | CN | Professional, scientific and te… |
Telomir Pharmaceuticals, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34700/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34700 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34700 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34700 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34700}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Telomir Pharmaceuticals, Inc. (id: 34700)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.